This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Cinpanemab in Early Parkinson’s Disease

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Treatments for Parkinson’s disease have limitations. Cinpanemab, a monoclonal antibody targeting aggregated α-synuclein, has been proposed as a potential disease-modifying therapy. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account